A MULTI-IMAGE PLATFORM FOR THE EVALUATION OF CELL METABOLISM. APPLICATION TO CANCER DIAGNOSIS AND CYTOTOXICITY OF AMYLOID OLIGOMERS

Operation co-funded by EU cohesion policy (European Regional Development Fund (ERDF)) under the programme Multi-regional Spain - ERDF (2014ES16RFOP002), managing authority: Subdirección General de Gestión del FEDER, de la Dirección General de Fondos Europeos del Ministerio de Hacienda.. The source names no beneficiary for this operation. Location: Province of Granada (NUTS ES614); Spain. Budget: total eligible expenditure EUR 119,790; EU co-financing EUR 95,832 (co-financing rate 80%), as stated by the source. Runs 2015-01-01 to 2018-12-31. Source: Kohesio, EU cohesion policy projects managed by national and regional authorities (not CORDIS); selected because its summary names quantum technology. Summary from Kohesio (English machine translation by the source): THE INCREASE IN LIFE EXPECTANCY IN EUROPE AND THE REST OF THE DEVELOPED COUNTRIES HAS LED TO A SIGNIFICANT INCREASE IN THE INCIDENCE OF DISEASES WITH THE GREATEST IMPACT ON OLDER GROUPS, SUCH AS NEURODEGENERATIVE DISEASES (ALZHEIMER OR PARKINSON), AS WELL AS A HIGHER INCIDENCE OF CANCER. FOR THIS REASON, THE COMMUNITY IS MAKING GREAT EFFORTS TO PROMOTE NEW DIAGNOSTIC TOOLS AND IMAGING TECHNIQUES TO FACILITATE THE DISCOVERY OF PHARMACOS, EARLY DIAGNOSIS AND MONITORING OF THE EFFECTIVENESS OF NEW TREATMENTS. These ASPECTS REPRESENT THE PRINCIPAL PILARES FOR THE PROGRESS DOES A PERSONALISED MEDICINE. TUMORAL CELLS SUBJECTING A reprogramming of their METABO-FENOTIPS, AND RECIENT RESEARCHS are deterring the PRIMORDIAL PEOPLE THAT THE SPECIFIC METABO-PHENOTIPES IN THE TUMORAL PROGRESS. THE POSSIBILITY OF PROMOTING THE LEAP BETWEEN DIFFERENT METABOLIC STATES IS, INCIPIENTLY, MODIFYING THE PARADIGM ON CANCEROUS CELL TRANSFORMATION, WITH DISRUPTIVE IMPLICATIONS FOR THE DESIGN OF PHARMACOS. THUS, THE ASSESSMENT OF THE CELLULAR METABOLIC STATE WILL HELP IN THE EARLY DIAGNOSIS OF TUMOR TISSUE, AS WELL AS IN NEW TREATMENTS. ALSO, SOME NEURODEGENERATIVE DISEASES ALSO HAVE DYSFUNCTIONS IN MITOCHONDRIAL FUNCTION AND ALTERED CELL METABOLISM, WHICH MAY BE RELATED TO THE CLINICAL ONSET OF DEMENTIA. THE RELATIONSHIP BETWEEN NEURODEGENERATIVE AMYLOID DISEASES AND METABOLISM MALFUNCTION HAS RECENTLY BEEN DISCOVERED AND IS ONLY IN ITS EARLY STAGES OF RESEARCH, SO VERY LITTLE IS KNOWN OF THIS DEPENDENCE AT THE CELLULAR LEVEL. before THIS CONTEXT, THIS PROJECT will explore the following ASPECTS: 1) TO CLARIFY THE FUNDAMENTAL ROLE OF METABOLIC REPROGRAMMING IN THE BIOLOGY OF TUMOR CELLS; 2) THE DEVELOPMENT OF A NANOTECH IMAGING PLATFORM FOR CANCER DIAGNOSIS AND PRE-CLINIC DISCOVERY OF NEW PHARMACOS; 3) OBTAIN KEY INFORMATION ON AMYLOID OLIGOMERS THAT CAUSE CYTOTOXICITY; AND 4) TO ELUCIDATE THE EFFECT OF AMYLOID OLIGOMERS ON CELL METABOLISM. TO ACHIEVE THESE OBJECTIVES, ADVANCED FLUORESCENCE [shortened; the full text is on the Kohesio page]

Original source.

Source: Kohesio (EU cohesion policy projects), European Commission, Directorate-General for Regional and Urban Policy (DG REGIO). Retrieved 2026-10-21. Licence: CC0 1.0 (Cohesion Open Data Platform, dataset 2014-2020 Kohesio projects). Selected metadata, adapted presentation; the publisher's record is authoritative. No endorsement by the source is implied. Licence: public domain dedication (CC0 1.0).

AI-assisted summary: The project focuses on evaluating cell metabolism for cancer diagnosis and the cytotoxicity of amyloid oligomers, co-funded by the EU with a budget of EUR 119,790. It ran from January 2015 to December 2018 in the Province of Granada, Spain. Suggested technology pillar: sensing. Generated by AI from the public source text; it may contain errors and the original source is authoritative.